RxDoctor Payments DataLook up a doctor →

Ning Yang

Neurology · Greeley, CONPI 1275809675

Payments from drug & device makers

$221,246in general payments, 2019–2025

Across 974 payments — averaging $227.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$94K
  • Ipsen Innovation$40K
  • UCB, Inc.$19K
  • Argenx US, Inc.$18K
  • AbbVie$15K
  • Amgen$9K
  • plus $27K from 54 others
$1,905in research payments, 2019–2025

Across 8 payments — averaging $238.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck Healthcare Kgaa$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)206$93,609
Ipsen Innovation25$39,950
UCB, Inc.59$18,512
Argenx US, Inc.44$17,870
AbbVie(2 entities)126$15,195
Amgen31$9,021
Sanofi29$7,570
Janssen Scientific Affairs, LLC11$4,687
TG Therapeutics, Inc.40$1,855
Merck Kgaa1$1,820
Livanova USA, Inc.5$1,112
Johnson & Johnson5$988
EMD Serono, Inc.34$829
Pfizer64$751
Lundbeck LLC19$721
Lilly USA, LLC34$694
Biogen26$631
Novartis29$585
SK Life Science, Inc.17$517
Neurocrine Biosciences, Inc.10$447
Teva Pharmaceuticals USA, Inc.33$420
CSL Behring9$321
Biohaven Pharmaceutical Holding Company Ltd.8$308
Abbott7$273
Mallinckrodt Hospital Products Inc.10$211
Alnylam Pharmaceuticals Inc.4$202
EDW Pharma, Inc.1$194
Tanabe Pharma America, Inc.8$178
Scilex Pharmaceuticals Inc.9$164
Neurelis, Inc.6$138
Bristol Myers Squibb7$123
ANI Pharmaceuticals, Inc.5$120
Biohaven Pharmaceuticals, Inc.1$115
Vanda Pharmaceuticals Inc.1$93
Grifols USA, LLC4$92
Jazz Pharmaceuticals Inc.3$80
Amneal Pharmaceuticals LLC4$78
Cala Health, Inc.2$78
Eisai Inc.4$74
Genentech USA, Inc.3$70
Axsome Therapeutics, Inc.2$58
MDD US Operations, LLC3$57
Azurity Pharmaceuticals, Inc.2$42
Banner Life Sciences, LLC2$42
Cycle Pharmaceuticals Inc2$36
Catalyst Pharmaceuticals, Inc.2$34
Sumitomo Pharma America, Inc.3$33
Merz Pharmaceuticals, LLC2$29
Springworks Therapeutics, Inc.1$26
Takeda Pharmaceuticals U.S.A., Inc.1$25
Acadia Pharmaceuticals Inc1$25
Adamas Pharmaceuticals, Inc.1$23
Impel Pharmaceuticals Inc.1$21
Otsuka America Pharmaceutical, Inc.1$18
Acorda Therapeutics, Inc1$17
Averitas Pharma Inc.1$17
Amylyx Pharmaceuticals, Inc.1$13
Sunovion Pharmaceuticals Inc.1$12
Medtronic1$12
Supernus Pharmaceuticals, Inc.1$11

How this compares

$221,246 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024
$198,042
Medicare patients
277
Services billed
17,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Greeley

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →